Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework.
Ontology highlight
ABSTRACT: CRISPR germline editing therapies (CGETs) hold unprecedented potential to eradicate hereditary disorders. However, the prospect of altering the human germline has sparked a debate over the safety, efficacy, and morality of CGETs, triggering a funding moratorium by the NIH. There is an urgent need for practical paths for the evaluation of these capabilities. We propose a model regulatory framework for CGET research, clinical development, and distribution. Our model takes advantage of existing legal and regulatory institutions but adds elevated scrutiny at each stage of CGET development to accommodate the unique technical and ethical challenges posed by germline editing.
SUBMITTER: Evitt NH
PROVIDER: S-EPMC4699477 | biostudies-other | 2015
REPOSITORIES: biostudies-other
ACCESS DATA
